Core Points - PCI Biotech has announced an update regarding the evaluation of its future operations following the discontinuation of the PCL technology development due to insufficient progress and increased project risks [2][3] - The company's immediate priority is to preserve value while exploring strategic alternatives, including reverse mergers or a structured wind-down of operations [3][4] - Current operations are now focused on evaluating a new bioprocessing technology from an undisclosed party, leading to a decision to downsize personnel and extend the wind-down of operations [4][5] Company Overview - PCI Biotech is a biopharmaceutical company that develops and commercializes new technologies and therapies through its photochemical technology platform, which originated from research at the Oslo University Hospital [5]